Developmental Dysplasia of the Hip: Observation vs. Bracing

Sponsor
University of British Columbia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05869851
Collaborator
(none)
514
1
2
60
8.6

Study Details

Study Description

Brief Summary

Developmental dysplasia of the hip (DDH) is the most common childhood hip condition. When caught early, bracing is the most frequently used treatment; however, the brace can disrupt important mother-baby bonding time in the newborn period and present challenges to daily living. In babies with mild DDH, some studies have suggested that their hips may improve naturally as they grow and develop. This study will look at whether careful monitoring can be just as good as bracing for babies diagnosed with mild DDH less than 3 months of age, potentially avoiding unnecessary treatment. This will be the first study to look at this question with babies being treated at different hospitals in seven different countries, so the results will make an impact on children and families worldwide.

Condition or Disease Intervention/Treatment Phase
  • Other: Pavlik Harness
N/A

Detailed Description

Early detection of developmental dysplasia of the hip (DDH) is critical to optimize outcomes and minimize long-term disability and impact on quality of life for the child and family. The burden of disease is significant, with a DDH diagnosis in 15-20/1000 live births. Even when treated, DDH is a leading cause of early hip replacement or development of osteoarthritis in young adults, with DDH reportedly accounting for 10-92% of all hip replacements. Consideration must also be given, however, to potential overtreatment of infants, particularly in more mild cases of hip instability or radiological dysplasia. The hip joint is immature during infancy, and many cases of mild-to-moderate DDH can spontaneously resolve as the hip joint matures through development. Brace treatment for approximately six weeks is common to address this radiological dysplasia; however, it is unclear whether this approach provides significant benefit above careful observation by ultrasound. While a conservative, less costly approach, brace treatment is not without potential complications and drawbacks. There are still substantial healthcare costs and resources associated with brace treatment, but there is potentially an under-recognized psychosocial cost in regard to preventing or disrupting mother-infant bonding in the newborn period. Coping with the difficulties of brace treatment can be stressful for families, particularly mothers of newborns, but the ultimate psychosocial impact has been under-researched to date. There is evidence to suggest that events occurring during establishment of breastfeeding may impact the mother's ability to breastfeed. The UK Hip Trial (2005) also found that maternal anxiety and worries about their infant's hip were increased with early brace treatment, but were not elevated by ultrasound monitoring in isolation. Further, bracing can present challenges to daily family life, including dressing, mobility, and the need for specialized furniture, car seats and other equipment. If observation alone is non-inferior to bracing for radiological dysplasia, unnecessary treatment may be avoided, potentially decreasing both the psychosocial impact of disrupted mother-infant bonding and needed healthcare resources and costs.

The investigators propose to utilize the existing collaborations and infrastructure of the Global Hip Dysplasia Registry (GHDR) and leverage their collaboration with a group in the Netherlands performing a similar Treatment with Active Monitoring (TRAM) trial to determine whether observation alone is sufficient for infants with clinically stable radiologically abnormal hips. Specifically, the investigators aim to:

  1. Determine whether observation is non-inferior to bracing for infants with radiological dysplasia

  2. Provide a strong recommendation for management of this subset of DDH patients

  3. Compare findings to those of the Netherlands trial, which is being carried out in older patients (10-16 weeks at diagnosis)

This study will utilize the established infrastructure of the GHDR. GHDR was established in 2016, aimed at collecting longitudinal data on infants and children across the entire DDH spectrum. This specific trial will function as a targeted sub-study within the more extensive registry, and is a multi-centre, international prospective randomized non-inferiority trial designed to evaluate the necessity to treat infants with radiological hip dysplasia. In total, 14 of the centres currently contributing data to GHDR have agreed to participate and randomize eligible patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
514 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of Brace to Observation in Stable, Radiological Developmental Dysplasia of the Hip: A Multi-centre, International Randomized Controlled Non-inferiority Trial
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2027
Anticipated Study Completion Date :
Sep 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brace Treatment

Patients randomized to the brace treatment group will be treated with a Pavlik harness for a minimum of six weeks.

Other: Pavlik Harness
The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.

No Intervention: Active Monitoring

Patients randomized to the control group will undergo observation only.

Outcome Measures

Primary Outcome Measures

  1. Acetabular Index [2 years]

    A measure of the steepness of the acetabular roof assessed on radiograph.

Secondary Outcome Measures

  1. Alpha Angle [6 weeks]

    This angle is measured via ultrasound and refers to the angle between the acetabular roof and vertical cortex of the ilium.

  2. Beta Angle [6 weeks]

    This angle is measured via ultrasound and refers to the angle formed between the vertical cortex of the ilium and the triangular labral fibrocartilage (echogenic triangle).

  3. Percent Femoral Head Coverage [6 weeks]

    Measured via ultrasound and assesses the percentage of the femoral epiphysis covered by the acetabular roof.

  4. Number of Participants that Experienced Complications [2 years]

    Including development of femoral nerve palsy or avascular necrosis, progression of hip dysplasia, and need for further treatment.

  5. Parent/Guardian Perception Questionnaire [6 weeks]

    A survey assessing parent/guardian perceptions of caring for and bonding with their child. Each question is scored on a 7-point likert scale from 3 (strongly agree) to -3 (strongly disagree) with total scores ranging from 33 to -33.

  6. EuroQoL-5D [6 weeks, 1 year, 2 years]

    A survey assessing parent quality of life. Only the VAS portion of the questionnaire will be asked at each visit. The VAS is scored from 0 to 100 with higher scores indicating better health.

  7. EuroQol-5D Youth (Parent Proxy) [6 weeks, 1 year, 2 years (+6 and 18 months for Canadian centres only)]

    A survey assessing child quality of life. Only the VAS portion of the questionnaire will be asked at each visit. The VAS is scored from 0 to 100 with higher scores indicating better health.

  8. Toddler Quality of Life Questionnaire Short Form (Parent Proxy) [6 weeks, 1 year, 2 years (+6 and 18 months for Canadian centres only)]

    A survey assessing child quality of life. For each concept measured by the questionnaire, item responses are scored, summed and transformed on a scale from 0 to 100 with higher scores indicating better health.

  9. Parent/Guardian Satisfaction [6 weeks, 1 year, 2 years]

    Assessed using a VAS scored from 0 to 100 with higher scores indicating higher satisfaction.

  10. Healthcare Resource Use Questionnaire [6 weeks, 6 months, 1 year, 18 months, 2 years (Canadian centres only)]

    Parent/guardian reported questionnaire to collect information about visits to health care professionals, imaging, medication use, additional treatments related to the diagnosis of DDH, and out of pocket costs.

Other Outcome Measures

  1. Centre Edge Angle [5 years]

    To be assessed for participants who elect to take part in the Global Hip Dysplasia Registry and have available data. Measured on x-ray, it is the angle formed between the vertical axis of the pelvis and a line from the centre of the femoral head to the lateral edge of the acetabulum.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 12 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients presenting with radiological dysplasia of a clinically stable hip under three months (12 weeks) of age

  • Radiological dysplasia will be defined as a centred hip with an alpha angle between 43 and 60 degrees and a percent coverage of the femoral head (FHC) greater than 35 and less than 50, as measured on ultrasound exam

Exclusion Criteria:
  • Patients presenting with radiological dysplasia older than three months (12 weeks) of age

  • Patients presenting with clinical hip instability (Ortolani or Barlow positive) or findings of ultrasound instability with a stress test upon transverse view

  • Patients with known or suspected neuromuscular, collagen, chromosomal or lower-extremity congenital abnormalities or syndromic-associated hip abnormalities

  • Patients who received prior treatment (i.e. Pavlik harness) for DDH

Contacts and Locations

Locations

Site City State Country Postal Code
1 BC Children's Hospital Vancouver British Columbia Canada V6H3N1

Sponsors and Collaborators

  • University of British Columbia

Investigators

  • Principal Investigator: Kishore Mulpuri, FRCSC, University of British Columbia
  • Study Director: Emily Schaeffer, PhD, University of British Columbia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kishore Mulpuri, Professor, University of British Columbia
ClinicalTrials.gov Identifier:
NCT05869851
Other Study ID Numbers:
  • H20-03750
First Posted:
May 22, 2023
Last Update Posted:
May 25, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2023